The INK4a/ARF locus, encoding two tumor suppressor proteins, p16
Introduction
The INK4a/ARF locus, located on chromosome 9p21, is one of the most frequently targeted loci for inactivation in human cancer (Hall and Peters, 1996; Hainaut et al., 1997) . The INK4a/ARF gene encodes the p16
INK4a and p14 ARF tumor suppressor proteins. p16 INK4a specifically binds to and inhibits cyclin D-associated kinases resulting in hypophosphorylated retinoblastoma protein (Rb), a biologically active Rb species in tumor suppression (Weinberg, 1995) . It was later discovered that the same locus encodes a second protein through the usage of a separate promoter with a distinct first exon (exon 1b), which results in translation from an alternate reading frame (ARF) encoding a basic, nucleolar protein named p14 ARF in human (p19 ARF in mouse). ARF shares no amino acid homology with p16 INK4a protein and is activated by oncogenic stress signals, such as Ras, c-Myc, E1A and E2F (Serrano, 2000; Sherr, 2001) .
Mice lacking both INK4a and ARF alleles (INK4a À/À / ARF À/À ) are prone to spontaneous and carcinogeninduced tumor formation (Serrano et al., 1996) . Selective disruption of ARF alone recapitulates the phenotypic consequences seen in the INK4a À/À /ARF À/À double-null mice (Kamijo et al., 1997; Sharpless et al., 2004) . The ARF À/À cells are highly susceptible to Ras transformation and are resistant to both Ras-and culture-induced senescence (Groth et al., 2000) . In addition, exon 1b is frequently targeted in human cancers (Kumar et al., 1998; Iida et al., 2000; RandersonMoor et al., 2001; Rizos et al., 2001; Viswanathan et al., 2001) . The N-terminal portion (amino acids (aa) 1-64) of p14 ARF is necessary and sufficient for growth arrest Zhang et al., 1998) .
ARF functions to activate p53 through inhibition of MDM2 (Pomerantz et al., 1998; Zhang et al., 1998) . ARF interacts with MDM2 in the central acidic domain (CAD) (Weber et al., 2000b; Bothner et al., 2001 ) and antagonizes MDM2 E3 ligase function, resulting in p53 stabilization (Kamijo et al., 1998; Pomerantz et al., 1998; Stott et al., 1998; Zhang et al., 1998) . In fact, ARF inhibits several known functions of MDM2 toward p53, including MDM2's ability to block p53 transcription (Kamijo et al., 1998; Pomerantz et al., 1998; Stott et al., 1998) , and to ubiquitinate p53 (Honda and Yasuda, 1999; Midgley et al., 2000; Llanos et al., 2001) . In addition, ARF sequesters MDM2 in the nucleolus to prevent nucleo-cytoplasmic shuttling (Tao and Levine, 1999; Weber et al., 1999 Weber et al., , 2000b Zhang and Xiong, 1999) .
A growing body of evidence suggests that ARF possesses growth suppressive properties independent of p53. ARF À/À mice develop carcinomas and neurogenic tumors rarely seen in p53 À/À mice. In addition, c-Mycinduced lymphomas are more aggressive in ARF
À/À mice compared to either p53 À/À or ARF À/À mice alone (Eischen et al., 1999) . Triple knock mice nullizygous for ARF, p53 and Mdm2 develop multiple tumors at higher frequency than that of mice lacking both p53 and Mdm2 or p53 alone (Weber et al., 2000a) . Recently, it has been shown that tumors emerged significantly earlier in mice lacking both ARF and p53 than in the mice lacking p53 alone (Christophorou et al., 2006) . Notably, ARF can upregulate hypophosphorylated Rb and inhibits cell cycle progression in p21 À/À cells (Modestou et al., 2001 ). These observations indicate that ARF growth suppression function can be achieved independent of the p53-p21 pathway.
We have shown previously that MDM2 interacts with Rb and inhibits its growth suppressive function (Xiao et al., 1995) . MDM2 binds to Rb C-pocket, blocks Rb-E2F interaction and promotes cell cycle progression (Sdek et al., 2004) . Recently, we demonstrated that MDM2 facilitates Rb interaction with the 20S proteasome resulting in accelerated Rb degradation (Sdek et al., 2005) .
In this study, we investigated the role of ARF tumor suppressor protein in the regulation of Rb. Our results show that ARF inhibits MDM2-mediated Rb degradation by disruption of MDM2-Rb interaction. In addition, we show that lack of ARF led to reduced Rb protein levels independent of p53, and that ARF growth suppression function is impaired in the absence of Rb.
Results

Expression of p14
ARF increases Rb levels independent of p53 MDM2 has been shown to facilitate Rb degradation (Sdek et al., 2005; Uchida et al., 2005) . Given the critical role of ARF in regulation of MDM2, we investigated whether ARF can modulate MDM2-mediated Rb degradation. Co-expression of p14 ARF and Rb in p53-null H1299 cells led to a marked increase in Rb levels ( Figure 1a) . Transfection efficiency was comparable as shown by a comparable expression of co-transfected GFP. In addition, expression of p19 ARF by retroviral infection in H1299 cells also led to Rb accumulation. Importantly, ARF led to a significant increase in hypophosphorylated Rb (Figure 1b) .
p14
ARF upregulates Rb in an MDM2-dependent manner Rb consists of the N-terminus, the central portion (A-B domain) and the C-pocket (Figure 2a) . The A-B domain, referred to as the Rb small pocket (RbSP), binds to several viral oncoproteins and a subset of cellular proteins. The Rb large pocket (RbLP), containing the RbSP and C-pocket, is required for Rb growth suppressive function. As the Rb C-pocket binds to MDM2 (Xiao et al., 1995; Sdek et al., 2004) , we examined the role of Rb C-pocket in ARF-mediated Rb upregulation. H1299 cells were co-transfected with RbLP or RbSP and p14 ARF expression plasmids. Western-blot analysis showed that co-expression of ARF led to a significant increase in RbLP, but not RbSP proteins (Figure 2b ), suggesting that the Rb Cpocket is critical for ARF effect on Rb. We next examined whether ARF could directly inhibit MDM2-mediated Rb degradation. As shown in Figure 2c , expression of ARF-stabilized MDM2, consistent with previous reports (Stott et al., 1998; Honda and Yasuda, 1999; Llanos et al., 2001) . Importantly, whereas MDM2 destabilized Rb, as expected, co-expression of ARF led to concomitant MDM2 and Rb stabilization (Figure 2c ), suggesting that ARF upregulates Rb through inhibition of MDM2. We then examined the effect of ARF on Rb in p53 À/À murine embryonic fibroblast (MEF) and p53
À/À cells. As shown in Figure 2d , ARF markedly induced Rb in p53 À/À MEF cells but failed to do so in p53
À/ÀÀ/À cells. Taken together, these data suggest that ARF inhibits MDM2 and upregulates Rb.
ARF inhibits colony foci formation independent of p53
The N-terminus of ARF (ARF-N; aa 1-64) is critical for ARF-mediated growth suppressive function. Notably, both p14 ARF and p19 ARF N-terminal domains contain MDM2-binding modules (Zhang et al., 1998; Weber et al., 2000b) . Thus, we examined the effects of wild type, ARF-N and ARF-C (aa 64-132) on the expression of MDM2 and Rb. Our results showed that whereas wild-type ARF and ARF-N promoted MDM2 expression, keeping with its reported ability to block MDM2 E3 ligase activity (Figure 3a) , they also led to the accumulation of Rb protein ( Figure 3b ). In contrast, ARF-C was unable to affect either MDM2 or Rb (Figure 3a and b). We next examined the effect of ARF and ARF mutants on colony foci formation. As shown in Figure 3c , wild-type ARF as well as ARF-N (aa 1-64) significantly suppressed colony foci formation of H1299 cells. In contrast, ARF-C was less efficient in suppressing colony foci formation. These data, therefore, indicate that ARF can inhibit colony foci formation independent of p53, which is associated with its ability to induce Rb.
ARF inhibits MDM2-Rb interaction ARF binds to MDM2 in the CAD and inhibits MDM2-mediated p53 ubiquitination and degradation (Weber et al., 2000b; Bothner et al., 2001) . Notably, ARF can modulate MDM2 interaction with its binding partners, including KAP1 (Wang et al., 2005) and YY1 (Sui et al., 2004) . Since Rb interacts with MDM2 in the CAD (Sdek et al., 2004) , we examined whether ARF affects MDM2-Rb interaction. As shown in Figure 4a , MDM2-Rb interaction was readily detected by coimmunoprecipitation (IP) experiments (lane 3). Expression of wild-type p14 ARF led to a stable p14 ARF -MDM2 complex formation and, importantly, a significant reduction of MDM2-Rb interaction (lane 6). In contrast, ARF-C was unable to bind to MDM2 and had little effect on MDM2-Rb interaction (lane 9). In a reverse IP-Western experiment, expression of ARF also led to reduced MDM2-Rb interaction (Figure 4b ). In addition, we examined the expression levels of Rb protein in wild type and ARF À/À MEF cells. As shown in Figure 4c , ARF À/À MEF cells had reduced Rb protein levels compared to wild-type MEF cells. Taken together, these data suggest that ARF stabilizes Rb protein through inhibition of MDM2-Rb association.
Rb is important in ARF-mediated growth inhibition
To examine the role of Rb in ARF growth suppression function, we infected U2-OS cells with retrovirus encoding short hairpin RNAi for Rb or vector control (pMSCV). Knockdown of Rb was effective ( Figure 5a ) and led to an increase in cell proliferation (Figure 5b ). Retroviral infection of p19 ARF led to significant growth inhibition (60%) in wild-type U2-OS cells. In contrast, p19 ARF -induced cell growth inhibition was significantly attenuated (23%) in cells expressing shRb (Figure 5b ), indicating that Rb is essential for ARF-induced growth suppression. In addition, p19 ARF significantly inhibited cell growth in p53 À/À MEF cells but not in p53 (Figure 5c ), demonstrating that MDM2 is critical for ARF growth suppression independent of p53. ) and the effects are greater than those seen in Rb
À/À mice. Significantly, alteration of the ARF locus was also seen in tumors from Rb (Tsai et al., 2002) , indicating a selective advantage of ARF inactivation. Additionally, induction of growth arrest by ARF in immortalized cells is inhibited by simultaneous inactivation of both p53 and Rb but not by inactivation of p53 alone (Carnero et al., 2000) , suggesting that ARF has p53-independent activity by acting, in part, through the Rb pathway. Interestingly, ARF can inhibit E7-mediated Rb degradation (Pan et al., 2003) . These observations collectively imply a functional link between ARF and Rb.
Overexpression of MDM2 is associated with a variety of human tumors/cancers, including approximately 30% of human sarcomas (Momand et al., 1998) . It is well documented that MDM2 functions in p53-dependent and -independent pathways. Recently, we demonstrated that MDM2 binds to Rb at the C-terminus to promote the proteasome-dependent Rb degradation (Sdek et al., 2005) . In this study, we demonstrated that ARF inhibits MDM2 resulting in stabilization of Rb. First, the Rb C-pocket, a binding site for MDM2, is critical for ARFmediated Rb induction. Second, wild-type ARF and the ARF-N terminus capable of MDM2 interaction can stabilize Rb and inhibit cell growth. In contrast, the ARF-C mutant unable to bind to MDM2 cannot stabilize Rb and/or inhibit cell growth. Third, ARF fails to upregulate Rb in cells lacking MDM2. Fourth, ARF but not ARF-C inhibits MDM2-Rb interaction. Moreover, loss of ARF leads to downregulation of Rb protein levels in MEF cells. Importantly, depletion of Rb attenuates ARF growth suppression function. Notably, although our data show that ablation of Rb substantially impairs ARF growth suppression function, it has been reported that inhibition of Rb by E7 in triple knockout MEF (p53 ARF-C expressing plasmids for 24 h and treated with MG132 for 14 h. Cell lysates were subjected to immunoprecipitation using a control antibody CD19, SMP14 (an antibody specific for MDM2) (a), or XZ77 (an antibody specific for Rb) (b). The immunoprecipitated protein complexes were subjected to Westernblot analyses for Rb, MDM2 or myc-p14 ARF , as indicated. Total protein (60 mg) from transfected H1299 cells was directly loaded on the gel as control (input) for Rb, MDM2 or p14 ARF , respectively. (c) Wild-type or ARF-null MEFs were examined for Rb expression. Equal amounts of total protein (120 mg for Rb, 40 mg for p19 ARF and actin) were separated by SDS-PAGE and subjected to Western-blot analysis. (Weber et al., 2000a) . Although the reasons for this discrepancy are unclear, it is possible that E7-mediated inhibition of Rb is affected by ARF, which has been reported by others (Pan et al., 2003) . In addition, it should be noted that Rb knockdown does not completely impairs ARF-induced cell growth arrest, indicating that ARF can function independent of p53 and Rb pathways.
Taken together, these data indicate that ARF induces Rb through the inhibition of MDM2, suggesting a novel growth suppression function for ARF independent of p53. Interestingly, since ARF is a downstream target of E2F, activation of Rb would lead to inhibition of E2F activity resulting in downregulation of ARF expression. This feedback system would likely contribute to the tight control of ARF expression. c-Abl has been shown to phosphorylate MDM2 at tyrosine 394 and inhibit MDM2-mediated ubiquitination and nuclear export of p53 (Sionov et al., 1999 (Sionov et al., , 2001 Goldberg et al., 2002) . Recently, c-Abl is reported to phosphorylate MDM2 at tyrosine 276 and promote ARF-MDM2 interaction and sequestration of MDM2 in the nucleolus (Dias et al., 2006) . Notably, this phosphorylation site (Y276) is in proximity to the Rbbinding domain (aa 254-264) of MDM2. Thus, it is plausible that c-Abl might affect Rb levels by enhancing ARF-MDM2 interaction and MDM2 nucleolar localization.
Recently, it was reported that ARF promotes Rb accumulation through inhibition of Tip60-dependent acetylation (Leduc et al., 2006) . Interestingly, acetylation of Rb C-pocket at lysine 873 and lysine 874 appears to enhance MDM2-Rb interaction (Chan et al., 2001; Nguyen et al., 2004) . Therefore, it is plausible that acetylation of Rb C-pocket may enhance or stabilize MDM2-Rb interaction resulting in accelerated Rb degradation. Although our data favor the possibility that ARF enhances Rb protein stability by direct inhibition of MDM2, it is possible that ARF can also modulate MDM2-Rb interaction through inhibition of Rb acetylation. Further experiments are needed to address these possibilities.
It is clear that Rb is regulated at multiple levels. In addition to gene mutations, such as deletion and point mutations that disrupt Rb structure and function, modulation of Rb protein phosphorylation remains a key regulatory mechanism for Rb function. Recent studies indicate that regulation of Rb protein stability appears to be an important neoplastic strategy (Ying and Xiao, 2006) , as exemplified by human papilloma viral oncoprotein E7 (Boyer et al., 1996; Berezutskaya et al., 1997; Wang et al., 2001) , cellular oncoproteins gankyrin (Higashitsuji et al., 2000) and MDM2 (Sdek et al., 2005; Uchida et al., 2005) . This study further À/À and p53 À/À mdm2 À/À MEF cells were infected with pBabe-p19 ARF retrovirus or pBabe vector alone. At 24 h after infection, 25 000 cells were reseeded on p35 plates and allowed to grow for 3 days. Total numbers of cells were counted using a hemacytometer. Two independent experiments in duplicates were performed. Expression of p19 ARF was analysed by Western-blot analysis (inset).
supports the notion that regulation of Rb protein stability is important in carcinogenesis. It is conceivable that inactivation of ARF leads to disruption of p53 and Rb pathways both of which play a critical role in human cancer development.
Materials and methods
Cell culture and plasmids H1299 and C33A cells were maintained in Dulbecco's modified Eagles medium (DMEM), supplemented with 10% fetal bovine serum (FBS) and 1% penicillin G/streptomycin sulfate (Invitrogen, Carlsbad, CA, USA) at 371C in a humidified 5% CO 2 incubator. Wild type and ARF À/À (provided by Dr Charles Sherr), p53
À/À and p53
À/À (provided by Dr Guillermina Lozano) MEF cells were maintained in DMEM supplemented with 12% FBS, 1% penicillin G/streptomycin sulfate, 2 mM L-glutamine (Invitrogen) and 100 mM MEM nonessential amino acids (Invitrogen).
pcDNA-p14 ARF-N and pcDNA-p14 ARF-C plasmids were provided by Dr Yanping Zhang. pBABE-puro-p19 ARF and pMSCV-puro-RbshRNA were provided by Dr Ronald A DePinho and Dr Scott Lowe, respectively.
Western-blot analyses and immunoprecipitation experiments
For Western-blot analyses, cells were washed with cold PBS and lysed in EBC250 lysis buffer (50 mM Tris-HCl, pH 8.0, 250 mM NaCl, 0.5% Nonidet P-40, 1 mM PMSF, 2 mg/ml leupeptin and 2 mg/ml aprotinin). Equal amounts of protein (20-100 mg) were separated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels, transferred to polyvinylidene difluoride membrane and hybridized to an appropriate primary antibody and horseradish peroxidaseconjugated secondary antibody for subsequent detection by enhanced chemiluminescence.
For IP-Western analyses, H1299 cells were transfected with plasmids using Lipofectamine2000 (Invitrogen). About 24 h after transfection, cells were treated with 20 mM MG132 for 14 h and lysed in EBC150 buffer (same as EBC250 except 150 mM NaCl). Whole-cell lysates were precleared with 75 ml of protein A/G slurry (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Total protein (1.5 mg) was incubated with 4 mg of antibody specific for MDM2 (SMP14), myc-tag (9E10) or control antibody against CD19 at 41C overnight. Immunoprotein complexes were resolved by SDS-PAGE followed by Western-blot analyses.
Specific antibodies were used to detect MDM2 (SMP14, Santa Cruz Biotechnology), Rb (G3-245, BD PharMingen), underphosphorylated Rb (G99-529, BD PharMingen), RbLP and RbSP proteins (a mixture of monoclonal antibodies XZ91 and XZ77, gift of Dr N Dyson), p19ARF (ab80, Abcam), p14ARF (C-18, Santa Cruz Biotechnology), GFP (FL, Santa Cruz Biotechnology), b-galactosidase (Z378A, Promega, Madison, WI, USA), actin (C-11, Santa Cruz Biotechnology) and myc (9E10, Santa Cruz Biotechnology).
Transfection and adenovirus/retrovirus infection Transient transfection was carried out using Lipofectamine2000 transfection reagent (Invitrogen) or calcium phosphate precipitation (Clontech Laboratories, Inc., Palo Alto, CA, USA). Equal amounts of total DNA plasmids were obtained by supplementing empty expression vector DNA. Cells were harvested 24 or 48 h after transfection.
Adenoviral-p14 ARF infection was performed as described previously (Sdek et al., 2005) in 2% FBS/DMEM for 2 h in a 371C incubator with 5% CO 2 . Infected cells were then washed with PBS and replaced with fresh 12% FBS/DMEM.
For high-efficiency retroviral infection, concentrated retroviruses (viral titers of 10 8 -10 9 cfu/ml) were prepared as described (Burns et al., 1993) . Briefly, 293FT cells were transiently transfected in triplicate using retroviral DNA and accessory plasmids by Lipofectamine2000. At 12 h after transfection, the media were changed; 48 h later, the supernatant was collected and centrifuged at 3000 r.p.m. for 10 min to remove debris and filtered through a 0.45 mM filter. The retroviral particles were then concentrated by ultra-centrifugation (27 000 r.p.m., 1 h 45 min at 41C), resuspended in fresh media supplemented with polybrene (10 mg/ml). Cells were selected in growth media supplemented with puromycin (2 mg/ ml) 24 h after infection.
Colony foci formation assay and cell growth analysis For colony foci formation, H1299 cells were transiently transfected with p14 ARF expression plasmid or vector using Lipofectamine2000. At 24 h after transfection, 10 000 cells were reseeded in duplicate on 60 mm plates and grown in 2% FBS/DMEM supplemented with G418 (800 ng/ml) (Invitrogen). The G418-containing media was changed every 3 days. About 18-21 days after selection, cells were rinsed with Â 1 PBS and then stained with 0.5% crystal violet (C-3886, SigmaAldrich, St Louis, MO, USA) solution in 70% ethanol. Another set of plates was trypsinized and cell numbers were counted using a hemocytometer.
For cell growth analysis, U2-OS or MEF cells were infected with concentrated pBABE-puro or pBABE-p19ARF retrovirus. At 24 h after infection, 25 000 infected cells were reseeded onto 35 mm dishes and grown for 3 days in 10% FBS/DMEM supplemented with puromycin (0.5 mg/ml). Cell numbers were quantified using a hemocytometer. At least two independent experiments in duplicates were performed.
